Πλοήγηση ανά Συγγραφέα "Fumoleau, P."
-
Article
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: A study of the EORTC early clinical studies group (ECSG)
Pavlidis, Nicholas; Aamdal, S.; Awada, Ahmad; Calvert, H.; Fumoleau, P.; Sorio, R.; Punt, C.; Verweij, J.; Oosterom, A. T. Van; Morant, R.; Wanders, J.; Hanauske, A. R. (2000)Purpose: In a phase II trial, the activity of carzelesin, a cyclopropylpyrroloindole prodrug analog, was assessed. Patients and methods: Carzelesin was used as second- or third-line chemotherapy in patients with breast, ...
-
Article
Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group
Briassoulis, E. Ch; Pavlidis, Nicholas; Terret, C.; Bauer, J.; Fiedler, W.; Schöffski, P.; Raoul, J. L.; Hess, D.; Selvais, R.; Lacombe, D.; Bachmann, P.; Fumoleau, P. (2003)The activity of glufosfamide (β-D-glucopyranosyl-N,N′ -di-(2-chloroethyl)-phosphoric acid diamide) against pancreatic cancer was investigated in a multicentre, phase II clinical study. Chemotherapy-naïve patients with ...
-
Article
Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer
Kerbrat, P.; Dieras, V.; Pavlidis, Nicholas; Ravaud, A.; Wanders, J.; Fumoleau, P. (2003)LU 103793 is a synthetic analogue of Dolastatin 15 that inhibits tubulin polymerisation. The aim of this study was to evaluate the efficacy and tolerability of LU 103793 in patients with metastatic breast cancer who had ...
-
Article
Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG)
Chollet, P.; Schöffski, P.; Weigang-Köhler, K.; Schellens, J. H. M.; Cure, H.; Pavlidis, Nicholas; Grünwald, V.; Boer, R. De; Wanders, J.; Fumoleau, P. (2003)S-1 is a new oral fluorinated pyrimidine derivate, in which the oral 5-fluorouracil (5-FU) prodrug, tegafur, was combined with two 5-FU-modulating substances, 5-chloro-2,4-dihydroxypyridine (gimeracil), and potassium oxonate ...